Business Context and Reporting Period
This Form 8-K is a current report filed by Orthofix Medical Inc. on July 1, 2026, regarding regulatory developments affecting its non-invasive bone growth stimulators. The report addresses changes in Medicare reimbursement policies following an FDA reclassification of these devices from Class III to Class II.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on regulatory status and its anticipated impact on reimbursement rates.
Material Changes
- Initial Change: Following an FDA order on April 16, 2026, the Centers for Medicare & Medicaid Services (CMS) modified billing requirements and fee schedules for specific devices (HCPCS codes E0747, E0748, and E0760) effective May 18, 2026.
- Reversal: On July 1, 2026, CMS issued revised guidance withdrawing the May 18 changes.
- Current Status: Devices furnished on or after May 18, 2026, are now to be processed and paid consistent with the treatment in effect prior to the FDA reclassification.
Guidance, Outlook, and Risks
Management expects average Medicare reimbursement for the affected codes to return to the rates in effect prior to May 18, 2026. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to factors such as the implementation of revised rules, changes in claim volumes, and payer behavior. The company disclaims any obligation to update these statements except as required by law.
Investor Verification Checklist
- Confirm the specific HCPCS codes (E0747, E0748, E0760) impacted by the CMS guidance reversal.
- Verify the exact reimbursement rates in effect prior to May 18, 2026, to assess the financial recovery.
- Monitor claim processing timelines to ensure CMS systems have updated to reflect the July 1 guidance.
- Review the company's most recent 10-K and 10-Q filings for detailed risk factors related to regulatory changes.